David Liebner, MD
Hematology & Oncology · Columbus, OHNPI 1174753537
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,435 of the $18,948 with a category attached, or 76.2%. Foundation Medicine, Inc. accounts for 76.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $9,396 and has fallen 87.5% since, to $1,170 in 2025.
Across 21 payments — averaging $902.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$14K
- Aadi Bioscience, Inc.$3K
- Deciphera Pharmaceuticals Inc.$1K
- AbbVie$196
Across 105 payments — averaging $5235.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$246K
- Blueprint Medicines Corporation$133K
- Epizyme, Inc.$63K
- PTC Therapeutics, Inc.$57K
- Eli Lilly$46K
- Adaptimmune LLC$5K
What the payments were for
- Consulting fees$14,43576%
- Speaking & faculty fees$3,93021%
- Travel & lodging$880%
- Food & beverage$3002%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 11 | $14,435 |
| Aadi Bioscience, Inc. | 5 | $3,147 |
| Deciphera Pharmaceuticals Inc. | 1 | $1,170 |
| AbbVie | 4 | $196 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$14,435
- FOUNDATIONONE LIQUID$11,015
- FOUNDATIONFOCUS$11,015
- FOUNDATIONONE HEME$11,015
- FOUNDATIONONE$11,015
- FYARRO$3,000
- VIMSELTINIB$1,170
How this compares
$18,948 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OgsiveoNirogacestat Hydrobromide | 15 | $371,293 |
| VerzenioAbemaciclib | 15 | $217,044 |
| AlecensaAlectinib Hcl | 11 | $187,358 |
| VotrientPazopanib Hcl | 11 | $108,642 |
| Pazopanib Hcl | 17 | $100,949 |
| SorafenibSorafenib Tosylate | 18 | $14,541 |
| EliquisApixaban | 13 | $9,850 |
| Dexamethasone | 15 | $251 |
| Prochlorperazine Maleate | 11 | $146 |
| Ondansetron Hcl | 13 | $94 |
| Levothyroxine Sodium | 16 | $72 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.